2. Search Result
Search Result
Results for "

adipocyte browning

" in MedChemExpress (MCE) Product Catalog:

28

Inhibitors & Agonists

7

Natural
Products

4

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-116771A
    CL 316243
    Maximum Cited Publications
    24 Publications Verification

    		 Adrenergic Receptor Metabolic Disease
    CL316243 is a highly potent selective β3-adrenoceptor agonist with a EC50 of 3 nM, but is an extremely poor to β1/2- receptors .CL316243 is a effective stimulant of adipocyte lipolysis and increases brown adipose tissue thermogenesis and metabolic rate . CL316243 has the potential for the treatment obesity, diabetes and urge urinary incontinence .
    CL 316243
  • HY-N0236
    Corylin
    5+ Cited Publications

    		 Antibiotic STAT Infection Metabolic Disease Cancer
    Corylin is an orally active flavonoid anti-inflammatory and osteogenic agent that inhibits IL-6-induced STAT3 promoter activity and STAT3 phosphorylation. Corylin also has anticancer, antiatherosclerotic, and ameliorating activity in hyperlipidemia and insulin resistance, inducing adipocyte browning and lipolysis through SIRT1 or β3-AR-dependent pathways .
    Corylin
  • HY-W012974
    3-Aminoisobutyric acid

    β-Aminoisobutyric acid; BAIBA

    		 Endogenous Metabolite Cardiovascular Disease Metabolic Disease
    3-Aminoisobutyric acid (β-Aminoisobutyric acid) has anti-inflammatory and antioxidant effects. 3-Aminoisobutyric acid increases the expression of brown adipocyte-specific genes in white adipose tissue and fatty acid β-oxidation in hepatocytes. 3-Aminoisobutyric acid attenuates insulin resistance and inflammation induced by palmitate or a high fat diet via an AMPK-PPARδ-dependent pathway in mice. 3-Aminoisobutyric acid is a catabolic metabolite of thymine and valine in skeletal muscle .
    3-Aminoisobutyric acid
  • HY-120657
    9-PAHSA

    		CGRP Receptor NF-κB Neurological Disease Metabolic Disease Inflammation/Immunology
    9-PAHSA is an orally active endogenous GPR120 agonist (EC50=18 μM). 9-PAHSA significantly inhibits LPS-induced inflammatory responses by blocking the NF-κB pathway. 9-PAHSA induces adipocyte browning, enhances glucose uptake and reduces lipid accumulation, while improving mitochondrial function and the survival rate of steatotic hepatocytes. In terms of neuroprotection, 9-PAHSA regulates the expression of REST and BDNF in the prefrontal cortex of diabetic mice, and effectively prevents spatial working memory deficits and abnormal social behaviors. 9-PAHSA does not directly regulate insulin secretion or improve systemic insulin sensitivity, and possesses specific anti-inflammatory, metabolic regulatory and neuroprotective properties. 9-PAHSA can be used in the research of diabetes-related cognitive impairment, obesity and non-alcoholic fatty liver disease .
    9-PAHSA
  • HY-N6711
    Equisetin

    		HIV Integrase Bacterial Antibiotic Reactive Oxygen Species (ROS) STAT AMPK 11β-HSD Infection Metabolic Disease
    Equisetin is an N-methylserine-derived acyl tetramic acid, quorum sensing inhibitor (QSI), herbicides and antibiotics. Equisetin specifically inhibits the anionic carriers of substrates in the inner mitochondrial membrane. Equisetin inhibits the activity of HIV-1 integrase, 11β-HSD1, and 2,4-dinitrophenol (Dnp)-stimulated ATPase (IC50 = ~8 nmol per mg of protein). Equisetin exhibits growth inhibition of bacteria, anti-inflammatory, amelioration of lipid-associated disorders, and cytotoxic effects .
    Equisetin
  • HY-101325
    (S,S)-BRL-37344 sodium

    		Drug Isomer Adrenergic Receptor Cardiovascular Disease Metabolic Disease
    (S,S)-BRL-37344 sodium is an isomer of BRL-37344 (HY-101325B). BRL-37344 is a β-adrenoceptor agonist with EC50 values of 5.3, 18 and 570 nM for β3, β2 and β1. BRL-37344 induces concentration-dependent increases in atria1 rate, relaxation of guinea pig trachea and lipolysis of brown adipocytes .
    (S,S)-BRL-37344 sodium
  • HY-14811
    Beloranib

    ZGN-440; CKD-732 free base

    		 MetAP NF-κB Metabolic Disease
    Beloranib (ZGN-440; CKD-732 free base) is a selective, irreversible inhibitor of methionine aminopeptidase MetAP2 that suppresses appetite and increases energy expenditure. Beloranib blocks the enzymatic cleavage of N-terminal methionine from nascent proteins by forming a covalent bond with MetAP2, thereby regulating fatty acid metabolism, adrenergic signaling, and hypothalamic NF-κB expression. Beloranib significantly reduces food intake, body weight, and fat accumulation, while improving glucose tolerance, insulin sensitivity, and lipid metabolism. Beloranib also elevates energy expenditure and fat oxidation levels, without affecting body temperature, spontaneous activity, or the inflammatory cytokine IL-1β. Beloranib can be used in research on obesity and hypothalamic obesity .
    Beloranib
  • HY-153813
    Z16078526

    		p38 MAPK Mitochondrial Metabolism Others
    Z16078526 induces endogenous Ucp1 expression, promotes p38 MAPK phosphorylation and lipolysis in primary mouse brown adipocytes. Z16078526 activates thermogenic gene expression and mitochondrial activity (uncoupled respiration) in mouse brown adipocytes. Z16078526 also stimulates thermogenesis in the mouse .
    Z16078526
  • HY-116771
    CL 316243 free acid
    Maximum Cited Publications
    24 Publications Verification

    		 Adrenergic Receptor Metabolic Disease
    CL316243 free acid is a highly potent selective β3-adrenoceptor agonist with a EC50 of 3 nM, but is an extremely poor to β1/2- receptors. CL316243 free acid is a effective stimulant of adipocyte lipolysis and increases brown adipose tissue thermogenesis and metabolic rate. CL316243 free acid has the potential for the treatment obesity, diabetes and urge urinary incontinence .
    CL 316243 free acid
  • HY-101325A
    (S,S)-BRL-37344

    		Drug Isomer Adrenergic Receptor Cardiovascular Disease Metabolic Disease
    (S,S)-BRL-37344 is an isomer of BRL-37344 (HY-101325B). BRL-37344 is a β-adrenoceptor agonist with EC50 values of 5.3, 18 and 570 nM for β3, β2 and β1. BRL-37344 induces concentration-dependent increases in atria1 rate, relaxation of guinea pig trachea and lipolysis of brown adipocytes .
    (S,S)-BRL-37344
  • HY-14811A
    Beloranib hemioxalate

    ZGN-440 hemioxalate; ZGN-433 hemioxalate; CDK732 hemioxalate

    		 NF-κB MetAP Metabolic Disease
    Beloranib (ZGN-440; CKD-732 free base) hemioxalate is a selective, irreversible inhibitor of methionine aminopeptidase MetAP2 that suppresses appetite and increases energy expenditure. Beloranib hemioxalate blocks the enzymatic cleavage of N-terminal methionine from nascent proteins by forming a covalent bond with MetAP2, thereby regulating fatty acid metabolism, adrenergic signaling, and hypothalamic NF-κB expression. Beloranib hemioxalate significantly reduces food intake, body weight, and fat accumulation, while improving glucose tolerance, insulin sensitivity, and lipid metabolism. Beloranib hemioxalate also elevates energy expenditure and fat oxidation levels, without affecting body temperature, spontaneous activity, or the inflammatory cytokine IL-1β. Beloranib hemioxalate can be used in research on obesity and hypothalamic obesity .
    Beloranib hemioxalate
  • HY-W770410
    9-PAHSA-13C4

    		Isotope-Labeled Compounds CGRP Receptor NF-κB Others
    9-PAHSA- 13C4 is 13C-labeled 9-PAHSA. 9-PAHSAis an orally active endogenous GPR120 agonist (EC50=18 μM). 9-PAHSAsignificantly inhibits LPS-induced inflammatory responses by blocking the NF-κB pathway. 9-PAHSAinduces adipocyte browning, enhances glucose uptake and reduces lipid accumulation, while improving mitochondrial function and the survival rate of steatotic hepatocytes. In terms of neuroprotection, 9-PAHSAregulates the expression of REST and BDNF in the prefrontal cortex of diabetic mice, and effectively prevents spatial working memory deficits and abnormal social behaviors. 9-PAHSAdoes not directly regulate insulin secretion or improve systemic insulin sensitivity, and possesses specific anti-inflammatory, metabolic regulatory and neuroprotective properties. 9-PAHSAcan be used in the research of diabetes-related cognitive impairment, obesity and non-alcoholic fatty liver disease .
    9-PAHSA-13C4
  • HY-153812
    AST 7062601

    AST070

    		 Anion Exchangers Metabolic Disease
    AST 7062601 (AST070) is a Ucp1 inducer that strongly induces endogenous Ucp1 expression in primary mouse brown adipocytes. Ucp1 refers to uncoupling protein, found in brown and beige fat cells. In mammals, UCP1 oxidizes fatty acids and uncouples ATP production in mitochondria to promote energy dissipation as heat. AST 7062601 can be used to study thermogenic, uncoupled respiration .
    AST 7062601
  • HY-120657S
    9-PAHSA-d4

    		Isotope-Labeled Compounds CGRP Receptor NF-κB Others
    9-PAHSA-d4 is the deuterium labeled 9-PAHSA. 9-PAHSA is an orally active endogenous GPR120 agonist (EC50=18 μM). 9-PAHSA significantly inhibits LPS-induced inflammatory responses by blocking the NF-κB pathway. 9-PAHSA induces adipocyte browning, enhances glucose uptake and reduces lipid accumulation, while improving mitochondrial function and the survival rate of steatotic hepatocytes. In terms of neuroprotection, 9-PAHSA regulates the expression of REST and BDNF in the prefrontal cortex of diabetic mice, and effectively prevents spatial working memory deficits and abnormal social behaviors. 9-PAHSA does not directly regulate insulin secretion or improve systemic insulin sensitivity, and possesses specific anti-inflammatory, metabolic regulatory and neuroprotective properties. 9-PAHSA can be used in the research of diabetes-related cognitive impairment, obesity and non-alcoholic fatty liver disease .
    9-PAHSA-d4
  • HY-118397
    RB394

    		PPAR Others
    RB394 is a potent dual sEH/PPARγ modulator isoform that promotes adipocyte browning and exhibits cardioprotective activity, and can be used to suppress metabolic syndrome.
    RB394
  • HY-176148
    ZGL-18

    		Mitochondrial Metabolism Metabolic Disease
    ZGL-18 is an uncoupling protein 1 (UCP1)-inspired mitochondrial uncoupler. ZGL-18 activates brown adipocytes and reduces mitochondrial membrane potential .
    ZGL-18
  • HY-N12515
    Pinuseldarone

    		Others Metabolic Disease
    Pinuseldarone (compound 1), extracted from Pinus eldarica needles regulats brown adipogenesis and thermogenesis .
    Pinuseldarone
  • HY-183094
    AM73

    		PGC-1α Metabolic Disease
    AM73 is a PGC-1α1 stabilizer. AM73 increases the expression levels of Ucp1 and Cidea in brown adipocytes, and enhances basal mitochondrial respiration and uncoupled respiration. AM73 regulates hypoxia, brown adipocyte differentiation, carbohydrate metabolism and insulin signaling pathways in brown adipocytes. AM73 alters the thermogenic process of white adipocytes. AM73 is applicable to the research of obesity and related metabolic disorders .
    AM73
  • HY-165098
    3-Aminoisobutyric acid sodium salt

    β-Aminoisobutyric acid sodium salt; BAIBA sodium salt

    		 Endogenous Metabolite Cardiovascular Disease Metabolic Disease
    3-Aminoisobutyric acid (β-Aminoisobutyric acid) sodium salt has anti-inflammatory and antioxidant effects. 3-Aminoisobutyric acid sodium salt increases the expression of brown adipocyte-specific genes in white adipose tissue and fatty acid β-oxidation in hepatocytes. 3-Aminoisobutyric acid sodium salt attenuates insulin resistance and inflammation induced by palmitate or a high fat diet via an AMPK–PPARδ-dependent pathway in mice. 3-Aminoisobutyric acid sodium salt is a catabolic metabolite of thymine and valine in skeletal muscle .
    3-Aminoisobutyric acid sodium salt
  • HY-N0236R
    Corylin (Standard)

    		Reference Standards Antibiotic STAT Infection Metabolic Disease Cancer
    Corylin (Standard) is the analytical standard of Corylin. This product is intended for research and analytical applications. Corylin is an orally active flavonoid anti-inflammatory and osteogenic agent that inhibits IL-6-induced STAT3 promoter activity and STAT3 phosphorylation. Corylin also has anticancer, antiatherosclerotic, and ameliorating activity in hyperlipidemia and insulin resistance, inducing adipocyte browning and lipolysis through SIRT1 or β3-AR-dependent pathways .
    Corylin (Standard)
  • HY-11032
    SM-350300

    		Others Metabolic Disease
    SM-350300 is a glucoprotein. SM-350300 stimulates lipolysis in white adipocytes by activating the cyclic AMP (cAMP) pathway, and upregulates the expression of lipolytic enzymes and uncoupling proteins (UCP1, UCP3) in brown adipose tissue (BAT) and white adipose tissue (WAT). SM-350300 reduces body weight by decreasing carcass fat while increasing lean muscle mass in metabolic disorder models. SM-350300 can be used for the study of metabolic disorders including obesity, type 2 diabetes, and cachexia .
    SM-350300
  • HY-183096
    AM31

    		PGC-1α Metabolic Disease
    AM31 is a PGC-1α1 stabilizer. AM31 enhances the protein stability of PGC-1α1, promotes protein accumulation and target gene activation. AM31 induces the expression of Ucp1 and Cidea in brown adipocytes. AM31 increases the levels of basal mitochondrial respiration and uncoupled respiration in brown adipocytes. AM31 can be used for the research of obesity and related metabolic disorders .
    AM31
  • HY-120657R
    9-PAHSA (Standard)

    		Reference Standards CGRP Receptor NF-κB Cardiovascular Disease Inflammation/Immunology
    Flumethrin (Standard) is the analytical standard of Flumethrin. This product is intended for research and analytical applications. 9-PAHSA is an orally active endogenous GPR120 agonist (EC50=18 μM). 9-PAHSA significantly inhibits LPS-induced inflammatory responses by blocking the NF-κB pathway. 9-PAHSA induces adipocyte browning, enhances glucose uptake and reduces lipid accumulation, while improving mitochondrial function and the survival rate of steatotic hepatocytes. In terms of neuroprotection, 9-PAHSA regulates the expression of REST and BDNF in the prefrontal cortex of diabetic mice, and effectively prevents spatial working memory deficits and abnormal social behaviors. 9-PAHSA does not directly regulate insulin secretion or improve systemic insulin sensitivity, and possesses specific anti-inflammatory, metabolic regulatory and neuroprotective properties. 9-PAHSA can be used in the research of diabetes-related cognitive impairment, obesity and non-alcoholic fatty liver disease .
    9-PAHSA (Standard)
  • HY-144026S
    9-PAHSA-d9

    		CGRP Receptor NF-κB Inflammation/Immunology
    9-PAHSA-d9 is the deuterium labeled 9-PAHSA (HY-120657). 9-PAHSA is an orally active endogenous GPR120 agonist (EC50=18 μM). 9-PAHSA significantly inhibits LPS-induced inflammatory responses by blocking the NF-κB pathway. 9-PAHSA induces adipocyte browning, enhances glucose uptake and reduces lipid accumulation, while improving mitochondrial function and the survival rate of steatotic hepatocytes. In terms of neuroprotection, 9-PAHSA regulates the expression of REST and BDNF in the prefrontal cortex of diabetic mice, and effectively prevents spatial working memory deficits and abnormal social behaviors. 9-PAHSA does not directly regulate insulin secretion or improve systemic insulin sensitivity, and possesses specific anti-inflammatory, metabolic regulatory and neuroprotective properties. 9-PAHSA can be used in the research of diabetes-related cognitive impairment, obesity and non-alcoholic fatty liver disease .
    9-PAHSA-d9
  • HY-120657S1
    9-PAHSA-d31

    		Isotope-Labeled Compounds CGRP Receptor NF-κB Others
    9-PAHSA-d31 is the deuterium labeled 9-PAHSA. 9-PAHSA is an orally active endogenous GPR120 agonist (EC50=18 μM). 9-PAHSA significantly inhibits LPS-induced inflammatory responses by blocking the NF-κB pathway. 9-PAHSA induces adipocyte browning, enhances glucose uptake and reduces lipid accumulation, while improving mitochondrial function and the survival rate of steatotic hepatocytes. In terms of neuroprotection, 9-PAHSA regulates the expression of REST and BDNF in the prefrontal cortex of diabetic mice, and effectively prevents spatial working memory deficits and abnormal social behaviors. 9-PAHSA does not directly regulate insulin secretion or improve systemic insulin sensitivity, and possesses specific anti-inflammatory, metabolic regulatory and neuroprotective properties. 9-PAHSA can be used in the research of diabetes-related cognitive impairment, obesity and non-alcoholic fatty liver disease .
    9-PAHSA-d31
  • HY-183095
    AM79

    		Metabolic Disease
    AM79 is a PGC-1α1 stabilizer. AM79 promotes the accumulation of endogenous PGC-1α1 protein, thereby activating its target genes. AM79 increases uncoupled mitochondrial respiration in brown adipocytes. AM79 induces the expression of Ucp1 and Cidea in brown adipocytes. AM79 can be used for the research of obesity and related metabolic disorders .
    AM79
  • HY-183097
    AM89

    		PGC-1α Metabolic Disease
    AM89 is a PGC-1α1 stabilizer. AM89 activates the expression of PGC-1α1 target genes and induces the upregulation of Ucp1 gene expression. AM89 is applicable for the research of obesity and related metabolic disorders .
    AM89
  • HY-101325B
    BRL-37344

    		Adrenergic Receptor Cardiovascular Disease Metabolic Disease
    BRL-37344 is a β-adrenoceptor agonist with EC50 values of 5.3, 18 and 570 nM for β3, β2 and β1. BRL-37344 induces concentration-dependent increases in atria1 rate, relaxation of guinea pig trachea and lipolysis of brown adipocytes .
    BRL-37344

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: